Evidence map›Paper›PMID 40575086›Full record

ArticleChemical & biomedical imaging2025

Chiral Strategy for Developing High-Performance Polymeric Gadolinium-Based MRI Contrast Agents for Vascular and Tumor Imaging.

Xinlan Zhou, Xinzhong Ruan, Xingjiang Li, Weiyuan Xu, Xinhui Xiao, Aiyi Chen, Yinghui Ding, Jilai Zhang, Gengshen Mo, Yong Jian and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical & biomedical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xinlan ZhouKey Laboratory of Theoretical Organic Chemistry and Function Molecule, Ministry of Education, School of Chemistry and Chemical Engineering, Hunan University of Science and Technology, Xiangtan, Hunan 411201, China.ORCID https://orcid.org/0009-0004-1784-6827
Xinzhong RuanDepartment of Radiology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China.
Xingjiang LiDepartment of Radiology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, Zhejiang 325000, China.
Weiyuan XuWenzhou Key Laboratory of Biophysics, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325001, China.
Xinhui XiaoWenzhou Key Laboratory of Biophysics, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325001, China.
Aiyi ChenWenzhou Key Laboratory of Biophysics, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325001, China.
Yinghui DingWenzhou Key Laboratory of Biophysics, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325001, China.
Jilai ZhangWenzhou Key Laboratory of Biophysics, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325001, China.
Gengshen MoWenzhou Key Laboratory of Biophysics, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325001, China.
Yong JianWenzhou Key Laboratory of Biophysics, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325001, China.
Xinyang WuMR Philips (China) Investment Co. Ltd., Building A1, No. 718 Lingshi Road, Jing'an District, Shanghai 200072, China.ORCID https://orcid.org/0009-0003-1012-5384
Fangfu YeWenzhou Key Laboratory of Biophysics, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325001, China.ORCID https://orcid.org/0000-0003-1279-105X
Zhiqiang WangDepartment of Radiology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou, Zhejiang 325000, China.
Yi LiKey Laboratory of Theoretical Organic Chemistry and Function Molecule, Ministry of Education, School of Chemistry and Chemical Engineering, Hunan University of Science and Technology, Xiangtan, Hunan 411201, China.ORCID https://orcid.org/0000-0002-4543-684X
Lixiong DaiWenzhou Key Laboratory of Biophysics, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325001, China.ORCID https://orcid.org/0000-0003-0983-2463

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Magnetic resonance imaging (MRI) is a critical tool in medical diagnostics, yet conventional MRI contrast agents (CAs) are often limited by their small-molecule nature, resulting in rapid clearance and low relaxivity. This study presents a chiral strategy for developing high-performance polymeric gadolinium-based CAs, PAA-EOB-GdA and PAA-EOB-GdB, tailored for enhanced vascular and tumor imaging. Notably, PAA-EOB-GdA, a chiral Gd-DOTA derivative integrated with sodium poly-(acrylic acid) (PAA), benefits from the optimized water exchange rate of chiral Gd-(III) complex and the polymer effect of PAA, exhibiting exceptionally high relaxivity (

Indexed as

Chiral Gadolinium ComplexExtended Imaging DurationHigh RelaxivityPolymeric MRI Contrast AgentsVascular and Tumor Imaging

Identifiers

PMID40575086
PMCPMC12188411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.